Livia Civitelli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Livia Civitelli has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Anna Teresa Palamara
Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
7 shared publications Enrico Garaci
IRCCS San Raffaele Pisana, Telematic University, Rome, Italy
6 shared publications- Maria Elena Marcocci
Department of Public Health and Infectious Diseases, Sapienza University of Rome, Laboratory affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Rome, Italy
5 shared publications - Claudio Grassi
Department of Neuroscience, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
4 shared publications - Giovanna De Chiara
Institute of Translational Pharmacology, CNR, Rome, Italy
4 shared publications - Roberto Piacentini
Department of Neuroscience, Università Cattolica del Sacro Cuore, Rome, Italy
4 shared publications
Latest Publications
- Open Access
- 15 April 2026
- Published by Elsevier in SSRN Electronic Journal
Stools and stool-derived extracellular vesicles from patients with Parkinson´s disease show alpha-synuclein seeding activity
Background: Parkinson’s disease (PD) is a neurodegenerative disorder that lacks a cure or reliable early biomarkers. PD pathology is driven by pathological aggregation of alpha-synuclein (αSyn) within the brain. Seed amplification assay (αSyn-SAA) is a highly sensitive diagnostic tool that detects pathological αSyn species in cerebrospinal fluid of PD patients. However, αSyn aggregates also occur in peripheral samples, including stools. In this study, we evaluated the potential diagnostic value of αSyn-SAA using stools from PD patients and healthy controls. Methods: Stools from PD patients (n=45) and healthy controls (HC; n=35) were assessed for the presence of αSyn species using slot blot profiling and ELISA assays and subjected to αSyn-SAA. Extracellular vesicles (EVs) were isolated from the subset of samples (n=5/group) using size exclusion chromatography and fully characterized. The seeding activity of stool-derived intact EVs was evaluated using αSyn-SAA. Findings: Protein extracts from both PD and HC stools contained pathological αSyn species, as detected by slot blot with pS129 and the conformation-specific antibodies MJFR-14 and 5G4. ELISA showed higher total αSyn levels in PD than HC samples, but no difference in aggregated αSyn. In stool protein extracts, αSyn-SAA showed 55.6% sensitivity and 60% specificity. Analysis of stool-derived EVs improved sensitivity to 100%, with 60% specificity, while pre-incubation of EVs with recombinant monomeric αSyn yielded 100% sensitivity and 100% specificity. Interpretation: Overall, stool-derived EV αSyn-SAA, especially with pre-incubation, shows promise as a non-invasive PD screening approach.
- 15 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessStools and stool-derived extracellular vesicles from patients with Parkinson´s disease show alpha-synuclein seeding activity
Background: Parkinson’s disease (PD) is a neurodegenerative disorder that lacks a cure or reliable early biomarkers. PD pathology is driven by pathological aggregation of alpha-synuclein (αSyn) within the brain. Seed amplification assay (αSyn-SAA) is a highly sensitive diagnostic tool that detects pathological αSyn species in cerebrospinal fluid of PD patients. However, αSyn aggregates also occur in peripheral samples, including stools. In this study, we evaluated the potential diagnostic value of αSyn-SAA using stools from PD patients and healthy controls. Methods: Stools from PD patients (n=45) and healthy controls (HC; n=35) were assessed for the presence of αSyn species using slot blot profiling and ELISA assays and subjected to αSyn-SAA. Extracellular vesicles (EVs) were isolated from the subset of samples (n=5/group) using size exclusion chromatography and fully characterized. The seeding activity of stool-derived intact EVs was evaluated using αSyn-SAA. Findings: Protein extracts from both PD and HC stools contained pathological αSyn species, as detected by slot blot with pS129 and the conformation-specific antibodies MJFR-14 and 5G4. ELISA showed higher total αSyn levels in PD than HC samples, but no difference in aggregated αSyn. In stool protein extracts, αSyn-SAA showed 55.6% sensitivity and 60% specificity. Analysis of stool-derived EVs improved sensitivity to 100%, with 60% specificity, while pre-incubation of EVs with recombinant monomeric αSyn yielded 100% sensitivity and 100% specificity. Interpretation: Overall, stool-derived EV αSyn-SAA, especially with pre-incubation, shows promise as a non-invasive PD screening approach.
- Open Access
Stools and stool-derived extracellular vesicles from patients with Parkinson’s disease contain alpha-synuclein species with seeding capacity
Background: Parkinson’s disease (PD) is a neurodegenerative disorder for which there is currently no cure or reliable biomarker for early detection or for evaluating the effectiveness of potential treatments. PD pathology is driven by misfolding and subsequent accumulation of alpha-synuclein (αSyn) protein into pathological aggregates within neurons and glial cells. Seed amplification assay (SAA) is a highly sensitive and specific diagnostic tool developed to detect pathological αSyn species in the cerebrospinal fluid (CSF) of PD patients. However, αSyn aggregates are present in multiple tissues and biosamples, including stools. In this study, we aimed to investigate the potential diagnostic value of SAA using stool samples from PD patients and healthy controls (HC). Methods: Stool samples from PD patients (n=45) and healthy controls (n=35) were analysed for the presence of αSyn species using slot blot assays with a panel of six αSyn antibodies, and ELISA assays. Samples were subjected to SAA, and the end-point products (SAA EP) were characterised using transmission electron microscopy (TEM). Extracellular vesicles (EVs) were isolated from the subset of samples (n=5 per group) using size exclusion chromatography and characterized by TEM. The seeding activity of isolated EVs was evaluated using SAA, followed by TEM analysis of SAA EP. Results: Protein extracts from both PD and HC stool samples revealed pathological αSyn species in the slot blot assay using the phosphorylated αSyn antibody, pS129 and conformation-specific antibodies, MJFR-14 and 5G4. ELISA showed significantly elevated total αSyn levels in PD samples compared to HC, although no differences in aggregated αSyn levels were detected. In stool protein extracts, SAA demonstrated 55.6% sensitivity and 60% specificity. When applied to stool-derived EVs from PD patients and controls, sensitivity increased to 100%, while specificity remained at 60%. Notably, SAA applied to stool-derived EVs pre-incubated with recombinant monomeric αSyn achieved 100% sensitivity and 100% specificity. Conclusion: These findings suggest that SAA applied to EVs isolated from stool samples, particularly after pre-incubation with recombinant monomeric αSyn, may serve as a valuable, non-invasive screening tool for the diagnosis of PD.
Open AccessStools and stool-derived extracellular vesicles from patients with Parkinson’s disease contain alpha-synuclein species with seeding capacity
Background: Parkinson’s disease (PD) is a neurodegenerative disorder for which there is currently no cure or reliable biomarker for early detection or for evaluating the effectiveness of potential treatments. PD pathology is driven by misfolding and subsequent accumulation of alpha-synuclein (αSyn) protein into pathological aggregates within neurons and glial cells. Seed amplification assay (SAA) is a highly sensitive and specific diagnostic tool developed to detect pathological αSyn species in the cerebrospinal fluid (CSF) of PD patients. However, αSyn aggregates are present in multiple tissues and biosamples, including stools. In this study, we aimed to investigate the potential diagnostic value of SAA using stool samples from PD patients and healthy controls (HC). Methods: Stool samples from PD patients (n=45) and healthy controls (n=35) were analysed for the presence of αSyn species using slot blot assays with a panel of six αSyn antibodies, and ELISA assays. Samples were subjected to SAA, and the end-point products (SAA EP) were characterised using transmission electron microscopy (TEM). Extracellular vesicles (EVs) were isolated from the subset of samples (n=5 per group) using size exclusion chromatography and characterized by TEM. The seeding activity of isolated EVs was evaluated using SAA, followed by TEM analysis of SAA EP. Results: Protein extracts from both PD and HC stool samples revealed pathological αSyn species in the slot blot assay using the phosphorylated αSyn antibody, pS129 and conformation-specific antibodies, MJFR-14 and 5G4. ELISA showed significantly elevated total αSyn levels in PD samples compared to HC, although no differences in aggregated αSyn levels were detected. In stool protein extracts, SAA demonstrated 55.6% sensitivity and 60% specificity. When applied to stool-derived EVs from PD patients and controls, sensitivity increased to 100%, while specificity remained at 60%. Notably, SAA applied to stool-derived EVs pre-incubated with recombinant monomeric αSyn achieved 100% sensitivity and 100% specificity. Conclusion: These findings suggest that SAA applied to EVs isolated from stool samples, particularly after pre-incubation with recombinant monomeric αSyn, may serve as a valuable, non-invasive screening tool for the diagnosis of PD.
- Top Cited PapersOpen Access
- 21 May 2025
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (6) , 413
The gut–brain axis in early Parkinson’s disease: from prodrome to prevention
Parkinson’s disease is the second most common neurodegenerative disorder and fastest growing neurological condition worldwide, yet its etiology and progression remain poorly understood. This disorder is characterized pathologically by the prion-like spread of misfolded neuronal alpha-synuclein proteins in specific brain regions leading to Lewy body formation, neurodegeneration, and progressive neurological impairment. It is unclear what triggers Parkinson’s and where α-synuclein protein aggregation begins, although proposed induction sites include the olfactory bulb and dorsal motor nucleus of the vagus nerve. Within the last 20 years, there has been increasing evidence that Parkinson’s could be triggered by early microbiome changes and α-synuclein accumulation in the gastrointestinal system. Gut microbiota dysbiosis that alters gastrointestinal motility, permeability, and inflammation could enable prion-like spread of α-synuclein from the gut-to-brain via the enteric nervous system. Individuals with isolated rapid eye movement sleep behavior disorder have a high likelihood of developing Parkinson’s and might represent a prodromal ‘gut-first’ subtype of the condition. The gut-first model of Parkinson’s offers novel gut-based therapeutic avenues, such as anti-, pre-, and pro-biotic preparations and fecal microbiota transplants. Crucially, gut-based interventions offer an avenue to treat Parkinson’s at early prodromal stages with the aim of mitigating evolution to clinically recognizable Parkinson’s disease characterized by motor impairment.
- 21 May 2025
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (6) , 413
Top Cited PapersOpen AccessThe gut–brain axis in early Parkinson’s disease: from prodrome to prevention
Parkinson’s disease is the second most common neurodegenerative disorder and fastest growing neurological condition worldwide, yet its etiology and progression remain poorly understood. This disorder is characterized pathologically by the prion-like spread of misfolded neuronal alpha-synuclein proteins in specific brain regions leading to Lewy body formation, neurodegeneration, and progressive neurological impairment. It is unclear what triggers Parkinson’s and where α-synuclein protein aggregation begins, although proposed induction sites include the olfactory bulb and dorsal motor nucleus of the vagus nerve. Within the last 20 years, there has been increasing evidence that Parkinson’s could be triggered by early microbiome changes and α-synuclein accumulation in the gastrointestinal system. Gut microbiota dysbiosis that alters gastrointestinal motility, permeability, and inflammation could enable prion-like spread of α-synuclein from the gut-to-brain via the enteric nervous system. Individuals with isolated rapid eye movement sleep behavior disorder have a high likelihood of developing Parkinson’s and might represent a prodromal ‘gut-first’ subtype of the condition. The gut-first model of Parkinson’s offers novel gut-based therapeutic avenues, such as anti-, pre-, and pro-biotic preparations and fecal microbiota transplants. Crucially, gut-based interventions offer an avenue to treat Parkinson’s at early prodromal stages with the aim of mitigating evolution to clinically recognizable Parkinson’s disease characterized by motor impairment.
- Open Access
- 25 November 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Brain-derived and in vitro-seeded alpha-synuclein fibrils exhibit distinct biophysical profiles
The alpha-synuclein (αSyn) seeding amplification assay (SAA) that allows the generation of disease-specific in vitro seeded fibrils (SAA fibrils) is used as a research tool to study the connection between the structure of αSyn fibrils, cellular seeding/spreading, and the clinicopathological manifestations of different synucleinopathies. However, structural differences between human brain-derived and SAA αSyn fibrils have been recently highlighted. Here, we characterize the biophysical properties of the human brain-derived αSyn fibrils from the brains of patients with Parkinson’s disease with and without dementia (PD, PDD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), and compare them to the ‘model’ SAA fibrils. We report that the brain-derived αSyn fibrils show distinct biochemical profiles, which were not replicated in the corresponding SAA fibrils. Furthermore, the brain-derived αSyn fibrils from all synucleinopathies displayed a mixture of ‘straight’ and ‘twisted’ microscopic structures. However, the PD, PDD, and DLB SAA fibrils had a ’straight’ structure, whereas MSA SAA fibrils showed a ‘twisted’ structure. Finally, the brain-derived αSyn fibrils from all four synucleinopathies were phosphorylated (S129). Interestingly, phosphorylated αSyn were carried over to the PDD and DLB SAA fibrils. Our findings demonstrate the limitation of the SAA fibrils modeling the brain-derived αSyn fibrils and pay attention to the necessity of deepening the understanding of the SAA fibrillation methodology.
- 25 November 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Open AccessBrain-derived and in vitro-seeded alpha-synuclein fibrils exhibit distinct biophysical profiles
The alpha-synuclein (αSyn) seeding amplification assay (SAA) that allows the generation of disease-specific in vitro seeded fibrils (SAA fibrils) is used as a research tool to study the connection between the structure of αSyn fibrils, cellular seeding/spreading, and the clinicopathological manifestations of different synucleinopathies. However, structural differences between human brain-derived and SAA αSyn fibrils have been recently highlighted. Here, we characterize the biophysical properties of the human brain-derived αSyn fibrils from the brains of patients with Parkinson’s disease with and without dementia (PD, PDD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), and compare them to the ‘model’ SAA fibrils. We report that the brain-derived αSyn fibrils show distinct biochemical profiles, which were not replicated in the corresponding SAA fibrils. Furthermore, the brain-derived αSyn fibrils from all synucleinopathies displayed a mixture of ‘straight’ and ‘twisted’ microscopic structures. However, the PD, PDD, and DLB SAA fibrils had a ’straight’ structure, whereas MSA SAA fibrils showed a ‘twisted’ structure. Finally, the brain-derived αSyn fibrils from all four synucleinopathies were phosphorylated (S129). Interestingly, phosphorylated αSyn were carried over to the PDD and DLB SAA fibrils. Our findings demonstrate the limitation of the SAA fibrils modeling the brain-derived αSyn fibrils and pay attention to the necessity of deepening the understanding of the SAA fibrillation methodology.
- Open Access
- 3 October 2024
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 13
Brain-derived and in vitro-seeded alpha-synuclein fibrils exhibit distinct biophysical profiles
The alpha-synuclein (αSyn) seeding amplification assay (SAA) that allows the generation of disease-specific in vitro seeded fibrils (SAA fibrils) is used as a research tool to study the connection between the structure of αSyn fibrils, cellular seeding/spreading, and the clinico-pathological manifestations of different synucleinopathies. However, structural differences between human brain-derived and SAA αSyn fibrils have been recently highlighted. Here, we characterize biophysical properties of the human brain-derived αSyn fibrils from the brains of patients with Parkinson’s disease with and without dementia (PD, PDD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA) and compare them to the ‘model’ SAA fibrils. We report that the brain-derived αSyn fibrils show distinct biochemical profiles, which were not replicated in the corresponding SAA fibrils. Furthermore, the brain-derived αSyn fibrils from all synucleinopathies displayed a mixture of- ‘straight’ and ‘twisted’ microscopic structures. However, the PD, PDD, and DLB SAA fibrils had a ‘straight’ structure, whereas MSA SAA fibrils showed a ‘twisted’ structure. Finally, the brain-derived αSyn fibrils from all four synucleinopathies were phosphorylated (S129). Interestingly, phosphorylated αSyn were carried over to the PDD and DLB SAA fibrils. Our findings demonstrate the limitation of the SAA fibrils modelling the brain-derived αSyn fibrils and pay attention to the necessity of deepening the understanding of the SAA fibrillation methodology.
- 3 October 2024
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 13
Open AccessBrain-derived and in vitro-seeded alpha-synuclein fibrils exhibit distinct biophysical profiles
The alpha-synuclein (αSyn) seeding amplification assay (SAA) that allows the generation of disease-specific in vitro seeded fibrils (SAA fibrils) is used as a research tool to study the connection between the structure of αSyn fibrils, cellular seeding/spreading, and the clinico-pathological manifestations of different synucleinopathies. However, structural differences between human brain-derived and SAA αSyn fibrils have been recently highlighted. Here, we characterize biophysical properties of the human brain-derived αSyn fibrils from the brains of patients with Parkinson’s disease with and without dementia (PD, PDD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA) and compare them to the ‘model’ SAA fibrils. We report that the brain-derived αSyn fibrils show distinct biochemical profiles, which were not replicated in the corresponding SAA fibrils. Furthermore, the brain-derived αSyn fibrils from all synucleinopathies displayed a mixture of- ‘straight’ and ‘twisted’ microscopic structures. However, the PD, PDD, and DLB SAA fibrils had a ‘straight’ structure, whereas MSA SAA fibrils showed a ‘twisted’ structure. Finally, the brain-derived αSyn fibrils from all four synucleinopathies were phosphorylated (S129). Interestingly, phosphorylated αSyn were carried over to the PDD and DLB SAA fibrils. Our findings demonstrate the limitation of the SAA fibrils modelling the brain-derived αSyn fibrils and pay attention to the necessity of deepening the understanding of the SAA fibrillation methodology.
- Open Access
Brain-derived and in vitro-seeded alpha-synuclein fibrils exhibit distinct biophysical profiles
The alpha-synuclein ( α Syn) seeding amplification assay (SAA) that allows the generation of disease-specific in vitro seeded fibrils (SAA fibrils) is used as a research tool to study the connection between the structure of α Syn fibrils, cellular seeding/spreading, and the clinico-pathological manifestations of different synucleinopathies. However, structural differences between human brain-derived and SAA α Syn fibrils have been recently highlighted. Here, we characterize biophysical properties of the human brain-derived α Syn fibrils from the brains of patients with Parkinson’s disease with and without dementia (PD, PDD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA) and compare them to the ‘model’ SAA fibrils. We report that the brain-derived α Syn fibrils show distinct biochemical profiles, which were not replicated in the corresponding SAA fibrils. Furthermore, the brain-derived α Syn fibrils from all synucleinopathies displayed a mixture of- ‘straight’ and ‘twisted’ microscopic structures. However, the PD, PDD, and DLB SAA fibrils had a ‘straight’ structure, whereas MSA SAA fibrils showed a ‘twisted’ structure. Finally, the brain-derived α Syn fibrils from all four synucleinopathies were phosphorylated (S129). Interestingly, phosphorylated α Syn were carried over to the PDD and DLB SAA fibrils. Our findings demonstrate the limitation of the SAA fibrils modelling the brain-derived α Syn fibrils and pay attention to the necessity of deepening the understanding of the SAA fibrillation methodology.
Open AccessBrain-derived and in vitro-seeded alpha-synuclein fibrils exhibit distinct biophysical profiles
The alpha-synuclein ( α Syn) seeding amplification assay (SAA) that allows the generation of disease-specific in vitro seeded fibrils (SAA fibrils) is used as a research tool to study the connection between the structure of α Syn fibrils, cellular seeding/spreading, and the clinico-pathological manifestations of different synucleinopathies. However, structural differences between human brain-derived and SAA α Syn fibrils have been recently highlighted. Here, we characterize biophysical properties of the human brain-derived α Syn fibrils from the brains of patients with Parkinson’s disease with and without dementia (PD, PDD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA) and compare them to the ‘model’ SAA fibrils. We report that the brain-derived α Syn fibrils show distinct biochemical profiles, which were not replicated in the corresponding SAA fibrils. Furthermore, the brain-derived α Syn fibrils from all synucleinopathies displayed a mixture of- ‘straight’ and ‘twisted’ microscopic structures. However, the PD, PDD, and DLB SAA fibrils had a ‘straight’ structure, whereas MSA SAA fibrils showed a ‘twisted’ structure. Finally, the brain-derived α Syn fibrils from all four synucleinopathies were phosphorylated (S129). Interestingly, phosphorylated α Syn were carried over to the PDD and DLB SAA fibrils. Our findings demonstrate the limitation of the SAA fibrils modelling the brain-derived α Syn fibrils and pay attention to the necessity of deepening the understanding of the SAA fibrillation methodology.
- Open Access
- 3 February 2022
- Published by Wiley in Advanced Healthcare Materials
- Vol. 11 (11) , 2102097
Bioorthogonally Cross‐Linked Hyaluronan–Laminin Hydrogels for 3D Neuronal Cell Culture and Biofabrication
Laminins (LNs) are key components in the extracellular matrix of neuronal tissues in the developing brain and neural stem cell niches. LN‐presenting hydrogels can provide a biologically relevant matrix for the 3D culture of neurons toward development of advanced tissue models and cell‐based therapies for the treatment of neurological disorders. Biologically derived hydrogels are rich in fragmented LN and are poorly defined concerning composition, which hampers clinical translation. Engineered hydrogels require elaborate and often cytotoxic chemistries for cross‐linking and LN conjugation and provide limited possibilities to tailor the properties of the materials. Here a modular hydrogel system for neural 3D cell cultures, based on hyaluronan and poly(ethylene glycol), that is cross‐linked and functionalized with human recombinant LN‐521 using bioorthogonal copper‐free click chemistry, is shown. Encapsulated human neuroblastoma cells demonstrate high viability and grow into spheroids. Long‐term neuroepithelial stem cells (lt‐NES) cultured in the hydrogels can undergo spontaneous differentiation to neural fate and demonstrate significantly higher viability than cells cultured without LN. The hydrogels further support the structural integrity of 3D bioprinted structures and maintain high viability of bioprinted and syringe extruded lt‐NES, which can facilitate biofabrication and development of cell‐based therapies.
- 3 February 2022
- Published by Wiley in Advanced Healthcare Materials
- Vol. 11 (11) , 2102097
Open AccessBioorthogonally Cross‐Linked Hyaluronan–Laminin Hydrogels for 3D Neuronal Cell Culture and Biofabrication
Laminins (LNs) are key components in the extracellular matrix of neuronal tissues in the developing brain and neural stem cell niches. LN‐presenting hydrogels can provide a biologically relevant matrix for the 3D culture of neurons toward development of advanced tissue models and cell‐based therapies for the treatment of neurological disorders. Biologically derived hydrogels are rich in fragmented LN and are poorly defined concerning composition, which hampers clinical translation. Engineered hydrogels require elaborate and often cytotoxic chemistries for cross‐linking and LN conjugation and provide limited possibilities to tailor the properties of the materials. Here a modular hydrogel system for neural 3D cell cultures, based on hyaluronan and poly(ethylene glycol), that is cross‐linked and functionalized with human recombinant LN‐521 using bioorthogonal copper‐free click chemistry, is shown. Encapsulated human neuroblastoma cells demonstrate high viability and grow into spheroids. Long‐term neuroepithelial stem cells (lt‐NES) cultured in the hydrogels can undergo spontaneous differentiation to neural fate and demonstrate significantly higher viability than cells cultured without LN. The hydrogels further support the structural integrity of 3D bioprinted structures and maintain high viability of bioprinted and syringe extruded lt‐NES, which can facilitate biofabrication and development of cell‐based therapies.
- Open Access
Bioorthogonally Cross-Linked Hyaluronan-Laminin Hydrogels for 3D Neuronal Cell Culture and Biofabrication
Laminins (LNs) are key components in the extracellular matrix of neuronal tissues in the developing brain and neural stem cell niches. LN-presenting hydrogels can provide a biologically relevant matrix for the 3D culture of neurons towards development of advanced tissue models and cell-based therapies for the treatment of neurological disorders. Biologically derived hydrogels are rich in fragmented LN and are poorly defined concerning composition, which hampers clinical translation. Engineered hydrogels require elaborate and often cytotoxic chemistries for cross-linking and LN conjugation and provide limited possibilities to tailor the properties of the materials. Here we show a modular hydrogel system for neural 3D cell culture, based on hyaluronan (HA) and poly(ethylene glycol) (PEG), that is cross-linked and functionalized with human recombinant LN 521 using bioorthogonal copper-free click chemistry. Encapsulated human neuroblastoma cells demonstrate high viability and grow into spheroids. Neuroepithelial stem cells (lt-NES) cultured in the hydrogels can undergo spontaneous differentiation to neural fate and demonstrate significantly higher viability than cells cultured without LN. The hydrogels further support the structural integrity of 3D bioprinted structures and maintain high viability of syringe extruded lt-NES, which can facilitate the development of advanced neuronal tissue and disease models and translation of stem cell-based therapies. The authors present an extracellular matrix mimicking hydrogel for 3D culture of neural cell models. Based on hyaluronic acid and poly(ethylene glycol), the hydrogel immobilizes recombinant laminin 521, associated with neuronal development. The study demonstrates support of neuroblastoma cell viability, spontaneous human neuroepithelial stem cell differentiation, and the protective effect of the hydrogels during bioprinting and syringe needle ejection.
Open AccessBioorthogonally Cross-Linked Hyaluronan-Laminin Hydrogels for 3D Neuronal Cell Culture and Biofabrication
Laminins (LNs) are key components in the extracellular matrix of neuronal tissues in the developing brain and neural stem cell niches. LN-presenting hydrogels can provide a biologically relevant matrix for the 3D culture of neurons towards development of advanced tissue models and cell-based therapies for the treatment of neurological disorders. Biologically derived hydrogels are rich in fragmented LN and are poorly defined concerning composition, which hampers clinical translation. Engineered hydrogels require elaborate and often cytotoxic chemistries for cross-linking and LN conjugation and provide limited possibilities to tailor the properties of the materials. Here we show a modular hydrogel system for neural 3D cell culture, based on hyaluronan (HA) and poly(ethylene glycol) (PEG), that is cross-linked and functionalized with human recombinant LN 521 using bioorthogonal copper-free click chemistry. Encapsulated human neuroblastoma cells demonstrate high viability and grow into spheroids. Neuroepithelial stem cells (lt-NES) cultured in the hydrogels can undergo spontaneous differentiation to neural fate and demonstrate significantly higher viability than cells cultured without LN. The hydrogels further support the structural integrity of 3D bioprinted structures and maintain high viability of syringe extruded lt-NES, which can facilitate the development of advanced neuronal tissue and disease models and translation of stem cell-based therapies. The authors present an extracellular matrix mimicking hydrogel for 3D culture of neural cell models. Based on hyaluronic acid and poly(ethylene glycol), the hydrogel immobilizes recombinant laminin 521, associated with neuronal development. The study demonstrates support of neuroblastoma cell viability, spontaneous human neuroepithelial stem cell differentiation, and the protective effect of the hydrogels during bioprinting and syringe needle ejection.
- Open Access
- 1 September 2021
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 60 (37) , 2773-2780
The Luminescent Conjugated Oligothiophene h-FTAA Attenuates the Toxicity of Different Aβ Species
- 1 September 2021
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 60 (37) , 2773-2780
Open AccessThe Luminescent Conjugated Oligothiophene h-FTAA Attenuates the Toxicity of Different Aβ Species
- Open Access
- 28 August 2019
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 12, 200
Inhibition of nSMase2 Reduces the Transfer of Oligomeric α-Synuclein Irrespective of Hypoxia
Recently, extracellular vesicles (EVs), such as exosomes, have been proposed to play an influential role in the cell-to-cell spread of neurodegenerative diseases, including the intercellular transmission of α-synuclein (α-syn). However, the regulation of EV biogenesis and its relation to Parkinson’s disease (PD) is only partially understood. The generation of EVs through the ESCRT-independent pathway depends on the hydrolysis of sphingomyelin by neutral sphingomyelinase 2 (nSMase2) to produce ceramide, which causes the membrane of endosomal multivesicular bodies to bud inward. nSMase2 is sensitive to oxidative stress, a common process in PD brains; however, little is known about the role of sphingomyelin metabolism in the pathogenesis of PD. This is the first study to show that inhibiting nSMase2 decreases the transfer of oligomeric aggregates of α-syn between neuron-like cells. Furthermore, it reduced the accumulation and aggregation of high-molecular-weight α-syn. Hypoxia, as a model of oxidative stress, reduced the levels of nSMase2, but not its enzymatic activity, and significantly altered the lipid composition of cells without affecting EV abundance or the transfer of α-syn. These data show that altering sphingolipids can mitigate the spread of α-syn, even under hypoxic conditions, potentially suppressing PD progression.
- 28 August 2019
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 12, 200
Open AccessInhibition of nSMase2 Reduces the Transfer of Oligomeric α-Synuclein Irrespective of Hypoxia
Recently, extracellular vesicles (EVs), such as exosomes, have been proposed to play an influential role in the cell-to-cell spread of neurodegenerative diseases, including the intercellular transmission of α-synuclein (α-syn). However, the regulation of EV biogenesis and its relation to Parkinson’s disease (PD) is only partially understood. The generation of EVs through the ESCRT-independent pathway depends on the hydrolysis of sphingomyelin by neutral sphingomyelinase 2 (nSMase2) to produce ceramide, which causes the membrane of endosomal multivesicular bodies to bud inward. nSMase2 is sensitive to oxidative stress, a common process in PD brains; however, little is known about the role of sphingomyelin metabolism in the pathogenesis of PD. This is the first study to show that inhibiting nSMase2 decreases the transfer of oligomeric aggregates of α-syn between neuron-like cells. Furthermore, it reduced the accumulation and aggregation of high-molecular-weight α-syn. Hypoxia, as a model of oxidative stress, reduced the levels of nSMase2, but not its enzymatic activity, and significantly altered the lipid composition of cells without affecting EV abundance or the transfer of α-syn. These data show that altering sphingolipids can mitigate the spread of α-syn, even under hypoxic conditions, potentially suppressing PD progression.